The HPV Vaccine Prevents Cervical Cancer, So Why Are Indian Parents Still Saying No?

The vaccine does not treat an existing infection. It trains the immune system to recognise and destroy the human papillomavirus before it can establish itself. Two strains, HPV 16 and HPV 18, cause roughly 70 percent of all cervical cancer cases globally. The quadrivalent vaccine (Gardasil) and the bivalent vaccine (Cervarix) both target these strains. India's domestically produced vaccine, Cervavac, developed by the Serum Institute of Pune, covers the same two high-risk strains and received approval from the Drugs Controller General of India in 2022.

The vaccine works best when given before any sexual exposure, which is why it is recommended for girls aged 9 to 14. A 2020 study published in The Lancet Oncology, tracking over 1.6 million women in Sweden over 11 years, found that girls vaccinated before age 17 had a 88 percent lower risk of developing cervical cancer compared to unvaccinated women. The protection is not symbolic. It is measurable and durable.

Three doses were the original protocol. For girls under 15, two doses given six months apart now provide equivalent immunity, a change that simplified school-based vaccination drives considerably.

India records approximately 1.25 lakh new cervical cancer cases every year and accounts for nearly 23 percent of global cervical cancer deaths, according to data from the Indian Council of Medical Research. It is the second most common cancer among Indian women aged 15 to 44. Most cases are caught late, at Stage III or Stage IV, because pelvic symptoms are normalised, gynaecological check-ups are irregular, and Pap smear screening remains low even in urban centres.

The vaccine addresses the upstream cause. Screening catches what the vaccine missed. The two are not alternatives; they work in sequence. A vaccinated girl still needs cervical screening in adulthood, because the vaccine does not cover every cancer-causing HPV strain. But her risk profile is substantially lower from the start.

The hesitancy is not random. It clusters around a few specific objections, most of which are medically incorrect but socially coherent.

The most common: the vaccine will make girls sexually active earlier, or signals that parents expect their daughters to be sexually active. This belief has no clinical basis. No study has found any behavioural change following HPV vaccination. A 2012 study published in Pediatrics, following over 1,400 girls in the United States, found zero association between receiving the HPV vaccine and earlier sexual debut or higher rates of sexually transmitted infections. The vaccine is a cancer prevention measure, administered in the same clinical context as the hepatitis B vaccine, which no parent refuses on similar grounds.

The second fear: side effects. The HPV vaccine has one of the most extensively monitored safety records of any vaccine in the world. Common side effects are arm soreness and brief dizziness after injection. Serious adverse events are rare and thoroughly documented. The Vaccine Adverse Event Reporting System in the US and equivalent bodies in India's pharmacovigilance programme have not found evidence linking the vaccine to infertility, autoimmune disease, or neurological harm, claims that circulate on WhatsApp and are medically unfounded.

The third objection is cost. Gardasil has historically been expensive in the private market. Cervavac changed this: priced significantly lower, it made the vaccine accessible to a wider population. The government's decision to include the HPV vaccine in the Universal Immunisation Programme, announced for girls aged 9 to 14, removes the cost barrier for families who use public health infrastructure.

Underneath the stated objections is something harder to address with a fact sheet. The HPV vaccine requires parents to acknowledge, at least implicitly, that their daughter will one day be sexually active. In a social context where girls' sexuality is managed rather than discussed, that acknowledgement feels threatening, not medically, but socially.

This is not unique to India. Hesitancy followed the vaccine's rollout in conservative communities across the United States, parts of Europe, and Japan. Japan suspended its national recommendation in 2013 following media coverage of adverse events that were later found to be unrelated to the vaccine. The suspension lasted nearly a decade. Cervical cancer rates among Japanese women born after 1994, the cohort that missed vaccination, have since risen sharply. Japan resumed its recommendation in 2022, but the damage to that cohort is not reversible.

The Indian context carries its own specific weight. A mother who pushes for her daughter's vaccination may face questions from in-laws. A school that runs a vaccination drive may receive parent complaints. Doctors in smaller towns report that fathers are more resistant than mothers, and that framing the vaccine as a cancer prevention measure, rather than an STI prevention measure, consistently improves uptake. The framing is not a trick. It is accurate. Cervical cancer is what the vaccine prevents. The route of transmission is a biological fact, not the clinical point.

Paediatricians and gynaecologists working in community health settings have identified a few approaches that shift hesitant parents:

• Lead with cancer, not with HPV. "This protects your daughter from cervical cancer" lands differently than "this protects against a sexually transmitted virus." Both are true. The first is the outcome that matters to the parent.
• Draw the hepatitis B parallel. Hepatitis B is also transmitted sexually, among other routes. It is also on the childhood immunisation schedule. Parents who vaccinated without hesitation for hepatitis B rarely have a coherent reason to treat HPV differently once the parallel is named.
• Name the timeline. A girl vaccinated at 10 or 11 is protected by the time she is 20 or 25, the age at which exposure risk becomes real. The vaccine is not about now. It is about then.
• Address the WhatsApp claims directly. Dismissing them as misinformation without engaging the specific claim leaves the fear intact. Name the claim, name the study that examined it, state the finding.

The conversation is uncomfortable precisely because it requires adults to think about their daughters' futures in ways that feel premature. That discomfort is real. The cancer it prevents is also real.

The hesitancy and the disease share the same root: a culture that finds it easier to avoid the subject of girls' sexual health than to protect it. The vaccine works on the body. The conversation has to work on everything else.